Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
12:21pm, Wednesday, 27'th May 2026
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
12:15pm, Wednesday, 27'th May 2026
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
12:11pm, Wednesday, 27'th May 2026
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
What's Going On With Black Diamond Therapeutics Stock Tuesday?
11:31am, Tuesday, 26'th May 2026
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
11:55am, Monday, 25'th May 2026
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
08:00am, Friday, 22'nd May 2026
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
07:09pm, Thursday, 21'st May 2026
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigatio
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
BDTX Shares Gain 11% in a Week: Here's What You Should Know
12:51pm, Monday, 11'th May 2026
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:30am, Thursday, 07'th May 2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
08:06am, Tuesday, 28'th Apr 2026
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
12:30pm, Thursday, 23'rd Apr 2026
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
12:30pm, Thursday, 23'rd Apr 2026
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
12:25pm, Thursday, 23'rd Apr 2026
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
